Latest filing published 05 Aug 2024 for Cerevel Therapeutics Holdings, Inc., €1.1B.
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Pfizer Inc discloses dealings in 17 companies, chiefly Neurogene Inc., Encysive Pharmaceuticals Inc and Icagen, Inc. In total, 79 filings cover trades dated from 1 April 2008 to 1 August 2024.
On the open market, the record shows 32 purchases worth €100.1M and 21 sales worth €656.5M. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
A typical purchase (the median) is worth €934k. On 5 out of 7 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 6 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +11.6%. This is a record of the past, not a forecast.
The newest entry dates from 5 August 2024: a transaction of €1.1B, in Cerevel Therapeutics Holdings, Inc. The last purchase on record was published on 23 March 2023, which is 1,311 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 76 declarations